|Articles|May 11, 2020
Parexel Supports Manufacturers With COVID-19 Risk Mitigation Offering
Advertisement
Parexel has unveiled its COVID-19 Risk Mitigation offering, so that manufacturers can safely and confidently continue operations through the COVID-19 pandemic. Parexel’s regulatory experts will partner with life sciences companies aiming to ensure business continuity during these challenging times by analyzing manufacturing operations to reduce the risk of viral contamination. This will be accomplished through a four-step methodology.
For more information, click here.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
- Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
Advertisement
Advertisement